Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Urologix
(OTCEM:ULGX)
Intraday
$0.0001
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$0.0001
0
[0.00%]
At close: Mar 8
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Urologix Stock (OTC:ULGX)
Urologix Stock (OTC: ULGX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, March 24, 2020
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Mar 24, 2020, 11:39AM
Tuesday, February 25, 2020
Stocks That Hit 52-Week Lows On Tuesday
Lisa Levin
-
Feb 25, 2020, 10:22AM
Tuesday, November 26, 2019
Stocks That Hit 52-Week Lows On Tuesday
Lisa Levin
-
Nov 26, 2019, 11:18AM
Tuesday, August 19, 2014
8-K from Urologix Shows CFO Brian Smrdel Resigned, Co. Has Named CEO Gregory Fluet as Interim CFO
Benzinga
-
Aug 19, 2014, 4:55PM
Urologix, Inc. Reports Q4 EPS of $(0.17), Down 113% YOY; Revenue of $3.30M, Down 27% YOY
Benzinga
-
Aug 19, 2014, 4:00PM
Tuesday, May 06, 2014
Urologix, Inc. Reports Q3 EPS of $(0.08), Unchanged YOY; Revenue of $3.40M, Down 24% YOY
Benzinga
-
May 6, 2014, 4:34PM
Thursday, April 10, 2014
Urologix, Inc. Reports Prelim. Q3 Sales $3.40M
Benzinga
-
Apr 10, 2014, 5:01PM
Tuesday, February 04, 2014
Urologix, Inc. Reports Q2 EPS of $(0.05), Up 38% YOY; Revenue of $3.81M, Down 15% YOY
Benzinga
-
Feb 4, 2014, 4:22PM
Tuesday, August 20, 2013
Urologix, Inc. Sees FY2014 Sales $15.0M-17.0M
Benzinga
-
Aug 20, 2013, 4:02PM
Urologix, Inc. Reports Q2 EPS of $(0.06), Up 25% YOY; Revenue of $4.18M vs $3.77M Est
Benzinga
-
Aug 20, 2013, 4:01PM
Friday, June 14, 2013
Can Companies Recover from a Nasdaq or NYSE Delisting?
Benzinga
-
Jun 14, 2013, 12:47PM
Wednesday, May 01, 2013
Urologix, Inc. Sees FY2013 Sales $16.0M-17.0M; Reaffirms Outlook
Benzinga
-
May 1, 2013, 4:34PM
Urologix, Inc. Reports Q3 EPS of $(0.05) vs $(0.06) Est; Revenue of $4.08M vs $3.85M Est
Benzinga
-
May 1, 2013, 4:17PM
Wednesday, April 17, 2013
Urologix Receives Extension from NASDAQ to Regain Compliance
Benzinga
-
Apr 17, 2013, 5:01PM
Monday, April 08, 2013
Urologix Reports Important Milestone in Prostiva(R) RF Therapy Licensing Deal
Benzinga
-
Apr 8, 2013, 9:03AM
Wednesday, January 30, 2013
Urologix Names Greg Fluet CEO
Benzinga
-
Jan 30, 2013, 9:02AM
Thursday, August 23, 2012
Urologix Reports Q4 EPS $-0.08; Revenues $4.5M
Benzinga
-
Aug 23, 2012, 4:01PM
Tuesday, July 17, 2012
Dougherty & Company Initiates Coverage on Urologix at Buy
Benzinga
-
Jul 17, 2012, 11:37AM
Friday, June 29, 2012
Urologix Announces Pricing of Follow-On Offering of 5.2M Shares of Common Stock at $0.75
Benzinga
-
Jun 29, 2012, 9:21AM
Friday, June 08, 2012
Urologix Amends Filing, Offering 5.2M Shares
Benzinga
-
Jun 8, 2012, 11:35AM
Wednesday, June 06, 2012
Morning Market Losers
Benzinga
-
Jun 6, 2012, 10:22AM
Tuesday, January 24, 2012
Urologix Reports 48% Increase in Sequential Revenue for Fiscal 2012 Second Quarter
Benzinga
-
Jan 24, 2012, 4:02PM
Thursday, January 12, 2012
Urologix Secures $2 Million Credit Facility
Benzinga
-
Jan 12, 2012, 4:00PM
Friday, January 06, 2012
Urologix Regains Nasdaq Minimum Bid Price Requirement
Benzinga
-
Jan 6, 2012, 3:00PM
Tuesday, September 06, 2011
MAKO Surgical and Urologix Hit New 52-Week Highs
Benzinga
-
Sep 6, 2011, 3:51PM
Urologix Announces Signing of an Exclusive Worldwide License for the Prostiva RF Therapy System for BPH
Benzinga
-
Sep 6, 2011, 8:41AM
Thursday, June 30, 2011
Urologix Regains Compliance with NASDAQ Minimum Bid Requirement
Benzinga
-
Jun 30, 2011, 4:03PM
Tuesday, December 29, 2009
New 52-Week High Stocks (ULGX, MSFT, OSIS, ANX)
Benzinga
-
Dec 29, 2009, 9:47AM
